Patents by Inventor John A. Ryals
John A. Ryals has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200025729Abstract: Methods and systems are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.Type: ApplicationFiled: February 26, 2019Publication date: January 23, 2020Applicant: Metabolon, Inc.Inventors: Michael V. Milburn, John A. Ryals, Lining Guo, Andrea Eckhart, Jacob Wulff, Adam D. Kennedy, Thomas J. Jönsson, Ryan Douglas Michalek, Bryan Wittmann, Matthew Mitchell
-
Patent number: 10267777Abstract: Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.Type: GrantFiled: October 7, 2016Date of Patent: April 23, 2019Assignee: Metabolon, Inc.Inventors: Michael V. Milburn, John A. Ryals, Lining Guo, Andrea Eckhart, Jacob Wulff, Adam D. Kennedy, Thomas J. Jönsson, Ryan Douglas Michalek, Bryan Wittmann, Matthew Mitchell
-
Publication number: 20180314790Abstract: Methods using a combination of metabolomics and computer technology to determine sequence variants with potential negative or detrimental effects and enable the classification of a variant with an unknown or uncertain clinical significance from VUS status to benign, pathogenic or advantageous are described. For example, methods of using metabolomics to expedite personalized medicine based on genomic sequence analysis are described. Using metabolic profiles to determine (or aid in determining) the significance of genetic variants and enable the identification of diagnostic variants (those variants having a detrimental health affect) for use in personalized medicine is described. Further, using metabolic profiles to determine the presence of advantageous variants that may have a positive effect on patient health is also described.Type: ApplicationFiled: November 4, 2015Publication date: November 1, 2018Inventors: Shaun Lonergan, John A. Ryals, Michael V Milburn, Adam Kennedy, Lining Guo, Kay A Lawton
-
Publication number: 20170089872Abstract: Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.Type: ApplicationFiled: October 7, 2016Publication date: March 30, 2017Inventors: Michael V. Milburn, John A. Ryals, Lining Guo, Andrea Eckhart, Jacob Wulff, Adam D. Kennedy, Thomas J. Jönsson, Ryan Douglas Michalek, Bryan Wittmann, Matthew Mitchell
-
Patent number: 8849577Abstract: Methods for metabolomically determining the biological affects of compounds are described.Type: GrantFiled: September 17, 2007Date of Patent: September 30, 2014Assignee: Metabolon, Inc.Inventors: John A. Ryals, Daniel P. Stevens, Michael V. Milburn
-
Publication number: 20080161228Abstract: Methods for metabolomically determining the biological affects of compounds are described.Type: ApplicationFiled: September 17, 2007Publication date: July 3, 2008Applicant: Metabolon Inc.Inventors: John A. Ryals, Daniel P. Stevens, Michael V. Milburn
-
Patent number: 6632981Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5′ region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: July 16, 2001Date of Patent: October 14, 2003Assignee: Novartis Finance CorporationInventors: Frederick Meins, Jr., Hideaki Shinshi, Herman C. Wenzler, Jan Hofsteenge, John A. Ryals, Christoph Sperisen
-
Patent number: 6262342Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5′ region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: July 9, 1999Date of Patent: July 17, 2001Assignee: Novartis Finance CorporationInventors: Frederick Meins, Jr., Hideaki Shinshi, Herman C. Wenzler, Jan Hofsteenge, John A. Ryals, Christoph Sperisen
-
Patent number: 5942662Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: November 14, 1997Date of Patent: August 24, 1999Assignee: Novartis Finance CorporationInventors: John A. Ryals, Christian T. Harms, Leslie B. Friedrich, James J. Beck, Scott J. Uknes, Eric R. Ward
-
Patent number: 5880328Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: March 9, 1999Assignee: Novartis Finance CorporationInventors: John A. Ryals, Eric R. Ward, George B. Payne, Mary B. Moyer, Frederich Meins, Jr.
-
Patent number: 5856154Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: January 5, 1999Assignee: Novartis Finance CorporationInventors: John A. Ryals, Danny C. Alexander, Robert M. Goodman, Eric R. Ward
-
Patent number: 5851766Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: December 22, 1998Assignee: Novartis Finance CorporationInventors: John A. Ryals, Christian Harms
-
Patent number: 5847258Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: December 8, 1998Assignee: Novartis Finance CorporationInventors: John A. Ryals, Mary B. Moyer, George B. Payne, Eric R. Ward
-
Patent number: 5804693Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: September 8, 1998Assignee: Novartis Finance CorporationInventors: Thomas D. Gaffney, John A. Ryals, Leslie B. Friedrich, Scott J. Uknes, Eric R. Ward, Helmut Kessmann, Bernardus T. Vernooij
-
Patent number: 5792904Abstract: Methods are provided for selecting parental plants having disease resistance and for using these plants in breeding programs. In one method of the invention, lesion mimic mutants are screened for either resistance to a pathogen of interest or for the expression of systemic acquired resistance (SAR) genes. Such mutants having the desired traits or expressing the desired genes are then used in breeding programs. Parent plants can also be selected based on the constitutive expression of SAR genes. These mutants are phenotypically normal yet exhibit a significant level of disease resistance. Also disclosed are plant mutants that do not express systemic acquired resistance genes even when induced by a pathogen and methods of use for such mutants.Type: GrantFiled: May 16, 1996Date of Patent: August 11, 1998Assignee: Novartis Finance CorporationInventors: John A. Ryals, Scott J. Uknes, Terrence Patrick Delaney, Eric R. Ward, Henry-York Steiner
-
Patent number: 5789214Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: August 4, 1998Assignee: Novartis Finance CorporationInventors: John A. Ryals, Leslie B. Friedrich, Scott J. Uknes, Eric R. Ward
-
Patent number: 5777200Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: July 7, 1998Assignee: Novartis Finance CorporationInventors: John A. Ryals, Danny C. Alexander, Robert M. Goodman, Jeffrey R. Stinson
-
Patent number: 5767369Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 31, 1995Date of Patent: June 16, 1998Assignee: Novartis Finance CorporationInventors: John A. Ryals, Danny C. Alexander, Robert M. Goodman, Jeffrey R. Stinson
-
Patent number: 5716849Abstract: The present invention is directed to the production of a polyketide antibiotic such as soraphen in a host via recombinant expression of the polypeptides needed to biologically synthesize the polyketide antibiotic. Polyketide synthase (PKS) genes encoding polypeptides necessary to synthesize soraphen are provided, along with methods for identifying and isolating the PKS genes needed to recombinantly biosynthesize any desired polyketide antibiotic. The cloned PKS genes may be transformed and expressed in a desired host organisms to produce soraphen for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of soraphen.Type: GrantFiled: December 14, 1996Date of Patent: February 10, 1998Assignee: Novartis Finance CorporationInventors: James M. Ligon, Thomas Schupp, James J. Beck, Dwight S. Hill, Snezana Neff, John A. Ryals
-
Patent number: 5689044Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 24, 1995Date of Patent: November 18, 1997Assignee: Novartis CorporationInventors: John A. Ryals, Leslie B. Friedrich, Scott J. Uknes, Eric R. Ward